论文部分内容阅读
自1993年10月起用阿昔洛韦（ACV）联合核糖核酸（RNA）治疗慢性乙型肝炎，重点观察对乙肝血清标志物转化的影响。现将近期疗效总结如下。资料与方法一、病例选择与分组本组67例慢性乙型肝炎，男56例，女11例，年龄18～61岁，病程6个月至5年。全部病例血清HBsAg、HBeAg、抗HBc阳
Since October 1993 acyclovir (ACV) combined with ribonucleic acid (RNA) treatment of chronic hepatitis B, with emphasis on the impact of hepatitis B serum markers. The recent curative effect is summarized as follows. Materials and Methods A case selection and group 67 cases of chronic hepatitis B, 56 males and 11 females, aged 18 to 61 years, duration of 6 months to 5 years. All cases of serum HBsAg, HBeAg, anti-HBc yang